Serum irisin level was significantly lower in the bladder cancer patients compared to the control group, demonstrating that serum irisin levels can be used for the diagnosis of bladder cancer (Taken et al., 2022). This evidence concerns the gene FNDC5 and urinary bladder carcinoma.